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Cannabinoid hyperemesis syndrome (CHS) is a rare constellation of clinical ﬁndings that includes a history of chronic heavy
marijuanause,severeabdominalpain,unrelentingnausea,andintractablevomiting.Astrikingcomponentofthishistoryincludes
the use of hot showers or long baths that help to alleviate these symptoms. This is an underrecognized syndrome that can lead to
expensive and unrevealing workups and can leave patients self-medicating their nausea and vomiting with the very substance that
is causing their symptoms. Long-term treatment of CHS is abstinence from marijuana use—but the acute symptomatic treatment
ofCHShasbeenastruggleformanyclinicians.ManystandardmedicationsusedforthesymptomatictreatmentofCHS(including
ondansetron, promethazine, and morphine) have repeatedly been shown to be ineﬀective. Here we present the use of lorazepam
as an agent that successfully and safely treats the tenacious symptoms of CHS. Additionally, we build upon existing hypotheses for
the pathogenesis of CHS to try to explain why a substance that has been used for thousands of years is only now beginning to cause
this paradoxical hyperemesis syndrome.
1.Introduction
Marijuana is a popular recreational drug that comes from
the Cannabis genus of ﬂowering plants. It also has several
medical applications—two of the most recognized being
its use as an antiemetic and an appetite stimulant [1, 2].
However, heavy prolonged use of this drug has been shown
to cause the poorly-understood, paradoxical cannabinoid
hyperemesis syndrome (CHS). Cannabinoid hyperemesis
syndrome was ﬁrst described by Allen et al. in 2004 [3].
Sontineni et al. described diagnostic criteria that include:
essential feature of chronic cannabis use; major features
of recurrent severe nausea and vomiting that resolves after
stopping cannabis use; supportive features of compulsive hot
baths with symptom relief, colicky abdominal pain, and no
evidence of gall bladder or pancreatic inﬂammation [4].
2. Case Presentation
A 28-year-old man with no past medical history presented to
the emergency department with a two-week history of severe
“10-out-of-10”colickyepigastricpainwithprofoundnausea,
15–20 episodes of vomiting daily, and decreased oral intake
for fear of triggering these symptoms. He denied alcohol and
tobacco use, but reported he had smoked two marijuana
cigars (each containing approximately 1.5 grams marijuana
bud) every day for the last ten years. As his symptoms of
nausea, vomiting, and abdominal pain intensiﬁed, he self-
medicated himself with increasing amounts of marijuana
and his symptoms became increasingly intense. The patient
reported that he initially got symptomatic relief with a hot
shower, though as his symptoms intensiﬁed, he required
increasingly longer bathing times that eventually progressed
to the patient soaking himself in hot baths for hours each
day. He stated that he had never experienced any of these
symptoms in the past. In the emergency department, the
patient’s vital signs were within normal limits and his
physical exam was signiﬁcant only for minor tenderness
to palpation in the epigastric region. The patient had no
focal neurological deﬁcits. The patient was admitted for
intravenous ﬂuid support, antiemetic therapy, and further
evaluation.
The patient’s medical evaluation revealed a complete
blood count, basic metabolic proﬁle, and hepatic proﬁle2 Case Reports in Medicine
that were within normal limits. An abdominal computerized
tomography (CT) scan was negative for pathology, an EGD
with biopsies showed only mild gastritis, and a gastric
emptying study showed mildly delayed gastric emptying.
In this patient, initial symptomatic treatment with on-
dansetron and morphine was unable to keep the patient
from having breakthrough episodes of nausea, vomiting, and
epigastric pain. The patient was unable to tolerate even a
clear liquid diet, and was extremely anxious about trying
to increase or advance his oral intake given the painful
episodes that food had triggered in the past. After ad-
ministering 1mg IV lorazepam, the patient improved at a
remarkable pace; within 10 minutes of administration he
no longer experienced nausea, abdominal, or food aversion.
Over the next 12 hours, he transitioned to a regular diet,
orallorazepam(1mgtablets),andwasabletodiscontinueall
other analgesic and antiemetic medications. The time from
marijuana cessation to complete resolution of symptoms
was approximately three weeks. The patient was discharged
with a seven-day prescription for lorazepam (1mg PO, twice
daily). The patient was contacted at 3 and 6 months after
discharge and he reported that, with sustained abstinence
from marijuana, he had no return of his symptoms.
3. Discussion and Conclusions
It has been hypothesized that the principal psychoactive con-
stituent of the cannabis plant, Delta-9-tetrahydrocannabinol
(THC) is the causative agent in CHS [3]. THC has been
shown to cause delayed gastric emptying and thermoregu-
latory disturbances via action on the cannabinoid receptor
type 1 (CB1) in the enteric plexus and central nervous
system, respectively [5]. Chronic stimulation of the CB1
receptors may result in the development of the gastrointesti-
nal and thermodysregulation symptoms in sensitive patients
[6], though more research needs to be conducted to further
elucidate what factors may predispose certain patients.
The earliest recorded uses of marijuana date from the 3rd
millennium BC [7], so why are we only now beginning to
see patients with CHS? We hypothesize that the emergence
of this syndrome is related to changes in patterns of plant
component utilization, and technological advances in the
production of marijuana that have dramatically increased
THC concentrations. In past decades, the stalks, leaves,
and buds of both male and female plants were consumed.
Modern analysis of the cannabis plant shows that the buds
(ﬂowers) of the female cannabis plant contain the highest
concentrations of THC and that the leaves can contain ten
times less THC than the buds, and the stalks one hundred
t i m e sl e s sT H C[ 8]. This new understanding has led to the
virtual elimination of stalks and leaves from consumption;
now modern users almost exclusively buy and consume the
highly-potent female buds and thus consume signiﬁcantly
higher amounts of THC. Furthermore, advances in breeding
andcultivationtechniques,includingtheuseofhydroponics,
cloning, high-intensity artiﬁcial lighting, and optimization
of growing conditions (e.g., ambient temperature and air
gas concentrations) have increased the potency of modern
cannabis. Recent research undertaken at the University of
Mississippi’s Potency Monitoring Project has found that
the mean THC content in conﬁscated cannabis samples
increased from 3.4% in 1993 to 8.8% in 2008 [9]. We believe
that the modern consumption of higher-potency prepara-
tions of higher-potency marijuana is causing profoundly
higher exposure to patients to THC and may be contributing
to the emergence of the cannabinoid hyperemesis syndrome.
Anticipatory nausea and vomiting is seen in patients
undergoing chemotherapy and lorazepam’s antiemetic,
amnestic, and anxiolytic properties have made it helpful
for treatment of this condition [10]. Lorazepam has also
been suggested in the treatment of cyclic vomiting syndrome
(CVS) [11]. One case report notes that benzodiazepines were
given for one week to a patient with CHS, but the patient
continued cannabis use, possibly limiting their eﬃcacy [12].
We found that lorazepam was extremely eﬀective in treating
our patient’s CHS. It helped the patient overcome his
conditioning to see food as a painful emetic trigger and also
helped to ameliorate the physical symptoms of CHS. The
addition of lorazepam to the patient’s regimen allowed for
rapid transition from a clear liquid to a regular diet, and
the ability to tolerate oral medications. We recommend that
lorazepam be considered in the treatment of CHS, especially
in patients with strongly conditioned food aversion.
It is unclear how this substance used by many to treat
nausea and stimulate appetite causes a condition with severe
nausea, vomiting, and anorexia with food anxiety. This lack
of understanding and delayed diagnosis can lead patients to
self-medicate with the very substance that is causing their
suﬀering.Assuch,patienteducationiscritical.Forproviders,
increased awareness of this syndrome and its inclusion in
the diﬀerential diagnosis of patients with intractable nausea
and vomiting may help prevent expensive and unrevealing
workups and decrease patient morbidity. Because many
patientswithCHShavebeenchronic,heavymarijuanausers,
it is important to assess if/how they may have incorporated
their substance use into their social lives and daily routines.
A thoughtful discussion about abstinence strategies, and
referral for mental health support and chemical dependence
treatment may also beneﬁt patients with cannabinoid hyper-
emesis syndrome.
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